efic a granenthal grant supports young scientists

-Can access the application form for 2012 in www.e-g-g.info

Madrid, April 2012.- young scientists from all over Europe are invited to enroll in the EFIC – Grünenthal grant (E-G – G) 2012, one of fellowships on more prestigious worldwide pain research. Granted by the European Federation of chapters of IASP (EFIC, by its acronym in English) and the company relating to world level in the field of pain, Grünenthal GmbH, this scholarship supports young scientists who are at the start of his career and carry out innovative and clinical projects on pain.

Grünenthal donates a total of € 200,000 for this biennial scholarship, which are shared among the award-winning scientists and aims at supporting them at the start of his career. Each individual scholarship has a value of up to € 40,000 per project for a duration of up to two years. The verdict of the jury is taken independently by the Research Committee of the EFIC.

Young scientists interested can submit their projects online through the website www.e-g-g.info until the end of 2012.

About the EFIC

The European Federation of chapters of IASP (EFIC, by its acronym in English) is a multidisciplinary professional organization in the field of research in pain, composed of the 35 so-called chapters of the International Association on the study of pain (IASP), which are scientific societies of pain officially approved by the IASP.

Established in 1993, the constituent chapters of the EFIC represents the societies of pain from 35 European countries and encompasses 20,000 scientists, doctors, professional nurses, physiotherapists, psychologists and other health professionals from all over Europe involved in the approach and research in pain.

About Grünenthal

Grünenthal group is a pharmaceutical company international, independent and family-owned based on research and headquartered in Aachen, Germany. Taking advantage of its position in the area of the treatment of pain, its aim is to become more patient-centred company in order to be a leader in therapeutic innovation.

Grünenthal is one of the last five pharmaceutical companies research-based with headquarters in Germany, which invests in a sustainable way in research and development. This investment amounted to about 25% of our sales in the year 2011. Grünenthal strategy as regards research and development focuses on select specific fields of therapy and the use of the latest technologies. We focus on the intense search for new ways to improve the treatment of pain, more effective and with fewer adverse reactions.

In total, the Grünenthal group has subsidiaries in 26 countries around the world and their products are sold in more than 155. Work approximately 4,500 employees in the Grünenthal group worldwide, of whom about 330 are in the region of Iberia. In 2011, the Grünenthal group worldwide reached an estimated turnover of € 947 M.

On the other hand, Grünenthal Pharma, the Spanish subsidiary of the Grünenthal group, ranked 17 in the Group of companies of between 250 and 500 employees of the prestigious ranking ‘ Best WorkPlaces 2011 Spain ’, produced by Great Place to Work ®.